ReviewCurrent molecular medicine2008
Posttranscriptional regulation of p53 and its targets by RNA-binding proteins.
Review in Current molecular medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 42 citations in OpenAlex.
- DLEU2 promotes the migration and invasion of papillary thyroid carcinoma cells through the ELAVL1/RCC2 axis.Functional & integrative genomics · 2026Article
- Pathogenic Roles of RNA-Binding Proteins in Sarcomas.Cancers · 2022Review
- Time-series transcriptomics and proteomics reveal alternative modes to decode p53 oscillations.Molecular systems biology · 2022Article
- Fine-tuning p53 activity by modulating the interaction between eukaryotic translation initiation factor eIF4E and RNA-binding protein RBM38.Genes & development · 2021Article
- Cancer the'RBP'eutics-RNA-binding proteins as therapeutic targets for cancer.Pharmacology & therapeutics · 2019Review
- Senescence promotes in vivo reprogramming through p16Aging cell · 2018Article
- Ferredoxin reductase is critical for p53-dependent tumor suppression via iron regulatory protein 2.Genes & development · 2017Article
- The DEAD-box RNA helicase DDX41 is a novel repressor of p21The Journal of biological chemistry · 2017Article
- Article
- Rbm24, an RNA-binding protein and a target of p53, regulates p21 expression via mRNA stability.The Journal of biological chemistry · 2014Article
- Article
- The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiation-induced apoptosis and mediates senescence via RSK- and p53-independent accumulation of p21WAF1/CIP1.Cell death & disease · 2013Article
- Glycogen synthase kinase 3 promotes p53 mRNA translation via phosphorylation of RNPC1.Genes & development · 2013Article
- Hsp70 is a novel posttranscriptional regulator of gene expression that binds and stabilizes selected mRNAs containing AU-rich elements.Molecular and cellular biology · 2013Article
- Serine 123 phosphorylation modulates p21 protein stability and activity by suppressing ubiquitin-independent proteasomal degradation.The Journal of biological chemistry · 2012Article
- p73 expression is regulated by RNPC1, a target of the p53 family, via mRNA stability.Molecular and cellular biology · 2012Article
- Growth inhibition by miR-519 via multiple p21-inducing pathways.Molecular and cellular biology · 2012Article
- Caspase-2 is required for DNA damage-induced expression of the CDK inhibitor p21(WAF1/CIP1).Cell death and differentiation · 2011Article
- Translational repression of p53 by RNPC1, a p53 target overexpressed in lymphomas.Genes & development · 2011Article
- Perturbations in ataxia telangiectasia mutant signaling pathways after drug-induced acute liver failure and their reversal during rescue of animals by cell therapy.The American journal of pathology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
p53 tumor suppressor plays a pivotal role in maintaining genomic integrity and preventing cancer development. The importance of p53 in tumor suppression is illustrated by the observation that about 50% human tumor cells have a dysfunctional p53 pathway. Although it has been well accepted that the activity of p53 is mainly controlled through post-translational modifications, recent studies have revealed that posttranscriptional regulations of p53 by various RNA-binding proteins also play a crucial role in modulating p53 activity and its downstream targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.